GO:0016594 glycine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016594 glycine binding is a molecular function defined as binding to glycine, aminoethanoic acid, the simplest amino acid and a major inhibitory neurotransmitter.
• Glycine binding is best characterized in NMDA receptors, glycine receptors, and glycine riboswitches, where it controls ion channel gating and gene regulation.
• Structural and pharmacological studies show that glycine occupies a conserved pocket in NMDA receptor GluN1/GluN3 subunits and is required for receptor activation.
• The glycine binding site is a validated drug target: ketamine and betaine modulate NMDA receptor activity through this site.
• Glycine binding also occurs in non-neuronal contexts, including RNA-binding proteins such as GRP7, where a glycine-rich domain mediates long-RNA binding and phase separation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of glycine-binding proteins in disease and neural function.
Description
Glycine binding (GO:0016594) is a molecular function that describes the selective, non-covalent interaction of a protein or RNA with glycine, the smallest amino acid and a key inhibitory neurotransmitter in the central nervous system. The term is defined by the Gene Ontology as binding to glycine, aminoethanoic acid, and it is distinct from glycine transport, glycine metabolism, and glycine receptor signaling as a whole. Because glycine is both a metabolic intermediate and a signaling molecule, proteins that bind glycine participate in processes ranging from fast synaptic inhibition to co-agonist gating of excitatory NMDA receptors. Researchers study glycine binding to understand how ligand recognition translates into conformational change, ion channel opening, and downstream cellular responses. In NMDA receptors, glycine is an obligatory co-agonist that binds the GluN1 and GluN3 subunits, and its occupancy is required for glutamate-driven channel activation. In glycine receptors, glycine binding triggers chloride flux and inhibitory neurotransmission, making the binding pocket a target for sedatives, anesthetics, and anticonvulsants. Beyond ion channels, glycine-rich domains in RNA-binding proteins such as GRP7 mediate long-RNA recognition and phase separation, showing that glycine binding can also be a protein-RNA interface phenomenon. From a drug discovery perspective, the glycine binding site of the NMDA receptor is clinically relevant: ketamine, a rapid-acting antidepressant and anesthetic, binds within the NMDA receptor channel and modulates glycine-dependent gating, while betaine has been proposed to target the glycine binding site as a therapeutic strategy. These findings make GO:0016594 a high-value annotation for neuroscience, pharmacology, and structural biology research.
glycine binding At A Glance
| GO ID | GO:0016594 |
|---|---|
| GO term | glycine binding |
| Ontology | molecular_function |
| Definition | Binding to glycine, aminoethanoic acid. |
| Synonyms | aminoacetic acid binding; aminoethanoic acid binding; Gly binding |
| Major function | Selective recognition of glycine as a ligand, co-agonist, or regulatory molecule by proteins and RNAs |
| Representative proteins | NMDA receptor subunits (GRIN1, GRIN3A, GRIN3B), glycine receptor subunits (GLRA1-4, GLRB), glycine riboswitch RNAs, GRP7 |
| Associated diseases | Neurological and psychiatric disorders, including NMDA receptor hypofunction, hyperekplexia, and depression models |
| Research methods | Electrophysiology, cryo-EM, X-ray crystallography, radioligand binding, CRISPR editing, and RNA biochemistry |
What Is GO:0016594?
GO:0016594 glycine binding is the molecular function of selectively and non-covalently interacting with glycine (aminoethanoic acid), the simplest amino acid. It is a binding function, not a catalytic or transport function, and it is assigned when a gene product physically associates with glycine as a ligand, co-agonist, or substrate-like molecule. The term is used across ion channels, riboswitches, and RNA-binding proteins, reflecting the broad biological roles of glycine recognition.
Why Is glycine binding Important in Cell Biology?
Glycine binding is important because it is the molecular trigger for some of the most fundamental signaling events in the nervous system and beyond. In NMDA receptors, glycine occupancy is a prerequisite for channel opening, so changes in glycine binding directly alter synaptic plasticity, learning, and memory. In glycine receptors, glycine binding mediates inhibitory neurotransmission, and mutations in the binding pocket cause hyperekplexia and related disorders. Pharmacologically, the glycine binding site is targeted by ketamine and betaine, linking this GO term to rapid antidepressant action and neuroprotection. In non-neuronal systems, glycine-rich domains in RNA-binding proteins use glycine-dependent interactions to bind long RNAs and drive phase separation, expanding the importance of glycine binding to RNA biology and biomolecular condensates. Finally, glycine riboswitches use tandem aptamers to bind glycine and regulate gene expression in bacteria, providing a model for understanding cooperative ligand recognition.
• Glycine binding is required for NMDA receptor co-agonist gating, a central mechanism in synaptic plasticity and memory.
• The glycine binding site of NMDA receptors is the target of ketamine, a rapid-acting antidepressant and anesthetic.
• Betaine has been proposed to modulate NMDA receptor function via the glycine binding site, suggesting therapeutic potential.
• Glycine receptors depend on glycine binding for inhibitory chloride currents, and binding-pocket mutations cause hyperekplexia.
• Glycine riboswitches use tandem aptamers to bind glycine and control bacterial gene expression, informing RNA engineering.
• Glycine-rich domains in proteins such as GRP7 mediate long-RNA binding and phase separation, linking glycine binding to RNA metabolism.
• Glycine binding is a druggable event, making it a target for neuropsychiatric and neurological drug discovery.
• CRISPR-based models of glycine-binding proteins enable causal tests of receptor function in disease.
• Structural studies of glycine binding inform rational design of subtype-selective ligands.
• Glycine binding assays are used in high-throughput screening for modulators of inhibitory and excitatory neurotransmission.
Molecular Mechanism of glycine binding
Ligand recognition and binding pocket architecture
In simple terms: Glycine fits into a pocket in the protein like a key in a lock.
Glycine binding is mediated by a structured pocket that positions the amino and carboxyl groups of glycine through hydrogen bonds and electrostatic interactions. In NMDA receptors, the GluN1 and GluN3 subunits contain a bilobed ligand-binding domain that closes around glycine, and structural studies show that glycine occupies a conserved site that is distinct from the glutamate site. In glycine receptors, the binding pocket is formed at subunit interfaces, and molecular dynamics simulations reveal how the pocket rearranges to accommodate glycine and how mutations alter ligand affinity. These structural features explain why glycine is recognized with high specificity over structurally related amino acids.
Conformational change and signal transduction
In simple terms: When glycine binds, the protein changes shape and sends a signal.
Glycine binding induces conformational changes that propagate from the ligand-binding domain to the ion channel or RNA switch. In NMDA receptors, glycine binding to GluN1 is a prerequisite for glutamate-dependent activation, and the two ligands act cooperatively to open the channel. In glycine receptors, glycine binding triggers rotation and tilting of transmembrane helices, opening a chloride-selective pore. In glycine riboswitches, glycine binding to tandem aptamers stabilizes a conformation that controls downstream gene expression, and the energetics of this switch depend on aptamer dimerization.
Cooperativity and allosteric modulation
In simple terms: Some glycine-binding systems respond more strongly when multiple glycines bind together.
Glycine binding can be cooperative or non-cooperative depending on the system. In tandem glycine riboswitches, ligand binding depends on aptamer dimerization, and double ligand occupancy is not strictly required for regulation, revealing an unexpected mode of allosteric control. In NMDA receptors, glycine binding is allosterically coupled to glutamate binding and to channel gating, and modulators such as ketamine can alter this coupling. Betaine has been proposed to interact with the glycine binding site, further highlighting the potential for allosteric modulation.
Glycine binding beyond ion channels: RNA and protein-RNA interfaces
In simple terms: Glycine can also help proteins grab RNA.
Glycine binding is not limited to neurotransmitter receptors. The glycine-rich domain of GRP7 is crucial for binding long RNAs and facilitating phase separation, demonstrating that glycine-rich sequences can mediate RNA recognition and condensate formation. This expands the functional scope of GO:0016594 to include protein-RNA interactions and biomolecular condensates, where glycine residues contribute to RNA binding affinity and specificity. Such findings are relevant to understanding how RNA-binding proteins organize into membraneless organelles and how mutations in glycine-rich domains may contribute to disease.
Pharmacology of the glycine binding site
In simple terms: Drugs can block or change the glycine binding site to alter brain signaling.
The glycine binding site is a validated pharmacological target. Ketamine binds within the NMDA receptor channel and modulates glycine-dependent gating, which is linked to its rapid antidepressant effects. Betaine has been proposed as a modulator of the glycine binding site, offering a potential strategy for conditions involving NMDA receptor dysfunction. In glycine receptors, the binding pocket is targeted by anesthetics and anticonvulsants, and understanding its dynamics can guide drug design. These pharmacological insights make glycine binding a central concept in neuropharmacology.
Key Genes Involved in GO:0016594 glycine binding
The following genes encode proteins and RNAs that bind glycine or contain glycine-binding domains, based on published structural, pharmacological, and biochemical studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRIN1 | NMDA receptor subunit containing the glycine binding site | Required for NMDA receptor co-agonist gating; target of ketamine and betaine |
| GRIN3A | NMDA receptor subunit with a glycine binding site | Modulates NMDA receptor function; studied for glycine affinity and subunit composition |
| GRIN3B | NMDA receptor subunit with a glycine binding site | Contributes to NMDA receptor diversity and glycine-dependent signaling |
| GRIN2A | NMDA receptor subunit that binds glutamate | Allosterically coupled to glycine binding; relevant to synaptic plasticity |
| GRIN2B | NMDA receptor subunit that binds glutamate | Modulates glycine-dependent gating and drug responses |
| GLRA1 | Glycine receptor alpha-1 subunit | Mediates inhibitory glycine currents; mutations cause hyperekplexia |
| GLRA2 | Glycine receptor alpha-2 subunit | Contributes to glycine receptor diversity and binding pharmacology |
| GLRA3 | Glycine receptor alpha-3 subunit | Involved in inhibitory neurotransmission and ligand recognition |
| GLRB | Glycine receptor beta subunit | Assembles with alpha subunits to form functional glycine receptors |
| GRP7 | RNA-binding protein with a glycine-rich domain | Glycine-rich domain binds long RNAs and drives phase separation |
| GldN | Glycine riboswitch-associated gene in bacteria | Model for tandem aptamer glycine binding and gene regulation |
| gcvT | Glycine cleavage system component | Studied in glycine metabolism and binding-related pathways |
| SHMT1 | Serine hydroxymethyltransferase | Glycine metabolism intersects with glycine-binding research |
| SHMT2 | Mitochondrial serine hydroxymethyltransferase | Links glycine metabolism to one-carbon metabolism |
| GLDC | Glycine decarboxylase | Glycine cleavage system enzyme relevant to glycine homeostasis |
| AMT | Aminomethyltransferase | Glycine cleavage system component |
| GCSH | Glycine cleavage system H protein | Lipoylated protein that interacts with glycine cleavage enzymes |
| DLD | Dihydrolipoamide dehydrogenase | Component of glycine cleavage system |
How Is glycine binding Regulated?
Glycine binding is regulated at multiple levels. In NMDA receptors, glycine binding is allosterically coupled to glutamate binding and channel gating, and modulators such as ketamine can alter this coupling. In glycine receptors, binding-pocket dynamics and subunit composition influence ligand affinity and cooperativity. In glycine riboswitches, ligand binding depends on aptamer dimerization and is energetically tuned by leader-linker interactions. In RNA-binding proteins, glycine-rich domains can be regulated by post-translational modifications and phase separation, which affect RNA binding. These regulatory mechanisms ensure that glycine binding is context-dependent and responsive to cellular signals.
glycine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRIN1 | NMDA receptor hypofunction; schizophrenia and depression models | Knockout and point-mutation models in neurons |
| GRIN3A | NMDA receptor diversity; neurodevelopmental disorders | Knock-in of glycine-binding site mutations |
| GLRA1 | Hyperekplexia; inhibitory neurotransmission defects | Point-mutation knock-in in mice |
| GRP7 | RNA processing and phase separation; neurodegeneration | Overexpression and glycine-rich domain deletion |
| GLRB | Glycine receptor assembly defects; hyperekplexia | Knockout and rescue models |
NMDA receptor dysfunction and neuropsychiatric disorders
Glycine binding to NMDA receptors is essential for excitatory neurotransmission, and altered glycine binding has been implicated in schizophrenia, depression, and other neuropsychiatric conditions. Ketamine, which modulates the NMDA receptor channel and glycine-dependent gating, produces rapid antidepressant effects, highlighting the clinical relevance of this binding site. Betaine has been proposed to target the glycine binding site, suggesting a potential therapeutic avenue for NMDA receptor-related disorders.
Glycine receptor mutations and hyperekplexia
Mutations in glycine receptor subunits, particularly GLRA1, can impair glycine binding and cause hyperekplexia, a neurological disorder characterized by exaggerated startle responses. Structural and dynamic studies of the glycine receptor binding pocket provide insight into how these mutations alter ligand recognition and channel gating. This makes glycine binding a direct molecular link to disease pathology.
Glycine-rich domains in RNA-binding proteins and disease
Glycine-rich domains in proteins such as GRP7 are critical for binding long RNAs and facilitating phase separation, and mutations in such domains may contribute to RNA processing diseases. Understanding how glycine-rich sequences mediate RNA binding can inform research on neurodegenerative diseases and cancer, where RNA-binding proteins are often dysregulated.
From glycine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of glycine binding abolish NMDA receptor function? | GRIN1 knockout or point-mutation knock-in |
| How do glycine receptor mutations affect inhibitory currents? | GLRA1 point-mutation knock-in |
| Can glycine binding be modulated pharmacologically? | Overexpression of NMDA receptor subunits and ligand-binding assays |
| What is the role of glycine-rich domains in RNA binding? | GRP7 glycine-rich domain deletion or tagged knock-in |
| How do glycine riboswitches regulate gene expression? | Bacterial riboswitch reporter assays |
| Which genes are essential for glycine-dependent signaling? | CRISPR library screening in neuronal cells |
How to Study the glycine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | 3D structure of glycine-bound receptor | NMDA and glycine receptor structure determination |
| X-ray crystallography | Atomic details of glycine binding pocket | Ligand recognition studies |
| Patch-clamp electrophysiology | Ion channel currents evoked by glycine | Functional testing of glycine binding mutants |
| Radioligand binding | Affinity and cooperativity of glycine binding | Pharmacological profiling |
| RNA immunoprecipitation | Protein-RNA interactions mediated by glycine-rich domains | GRP7 and RNA-binding protein studies |
| Phase separation assays | Condensate formation driven by glycine-rich domains | Biomolecular condensate research |
| CRISPR knockout screening | Genes required for glycine-dependent signaling | Functional genomics in neurons |
| Molecular dynamics simulation | Dynamics of glycine binding pockets | Glycine receptor and NMDA receptor dynamics |
Structural biology of glycine binding
X-ray crystallography and cryo-electron microscopy have revealed the atomic details of glycine binding in NMDA receptors and glycine receptors. These methods show how glycine is positioned in the binding pocket and how ligand binding induces conformational changes. Structural studies of ketamine-bound NMDA receptors further illustrate how drugs modulate the glycine binding site.
Electrophysiology and ligand-binding assays
Patch-clamp electrophysiology measures ion channel currents evoked by glycine, providing functional readouts of glycine binding and gating. Radioligand binding assays quantify affinity and cooperativity of glycine binding in receptor preparations. These methods are used to test mutations and pharmacological modulators.
RNA biochemistry and phase separation assays
For glycine-rich RNA-binding proteins such as GRP7, RNA immunoprecipitation, electrophoretic mobility shift assays, and phase separation assays measure how glycine-rich domains contribute to RNA binding and condensate formation. These approaches link glycine binding to RNA metabolism and biomolecular condensates.
CRISPR screening and functional genomics
CRISPR knockout and library screening can identify genes required for glycine-dependent signaling and receptor function. These methods enable unbiased discovery of modifiers of glycine binding and downstream pathways.
How CRISPR Can Be Used to Study GO:0016594 glycine binding
Knockout
CRISPR knockout of glycine-binding genes such as GRIN1 or GLRA1 eliminates the receptor subunit and abolishes glycine-dependent signaling, providing a clean loss-of-function model. These models are used to test whether glycine binding is required for synaptic plasticity, inhibitory neurotransmission, and behavior.
Point Mutation
Point mutations in the glycine binding pocket can selectively disrupt ligand recognition without deleting the entire protein. CRISPR point-mutation models are valuable for dissecting the contribution of individual residues to glycine affinity and gating.
Knock-in
Knock-in of disease-associated mutations in glycine-binding proteins, such as GLRA1 variants linked to hyperekplexia, allows study of mutant receptors in a physiological context. Knock-in models can also introduce epitope tags to track receptor localization and interactions.
Overexpression
Overexpression of glycine-binding proteins or their domains, such as GRP7 glycine-rich regions, enables biochemical and cell-based assays of RNA binding and phase separation. Overexpression of NMDA receptor subunits can be used to study glycine pharmacology and drug modulation.
How EDITGENE Supports glycine binding Research
Researchers studying glycine binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, RNA binding, or disease. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for glycine binding research.
Frequently Asked Questions About glycine binding
What is glycine binding?
Glycine binding (GO:0016594) is the molecular function of selectively and non-covalently interacting with glycine, the simplest amino acid, as defined by the Gene Ontology.
What genes are involved in glycine binding?
Key genes include GRIN1, GRIN3A, GRIN3B, GLRA1-4, GLRB, and GRP7, which encode proteins that bind glycine or contain glycine-binding domains.
What is the GO ID for glycine binding?
The GO ID for glycine binding is GO:0016594, a molecular_function term.
How does glycine bind to the NMDA receptor?
Glycine binds the GluN1 and GluN3 subunits of the NMDA receptor, inducing conformational changes required for channel activation.
Why is glycine binding important for the brain?
Glycine binding is required for NMDA receptor co-agonist gating and glycine receptor inhibitory signaling, both of which are essential for normal brain function.
What diseases are linked to glycine binding?
Altered glycine binding has been linked to neuropsychiatric disorders, hyperekplexia, and RNA-processing diseases involving glycine-rich domains.
How is glycine binding studied?
Common methods include cryo-EM, X-ray crystallography, patch-clamp electrophysiology, radioligand binding, and CRISPR-based functional assays.
Can CRISPR be used to study glycine binding?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models are used to test the causal role of glycine-binding proteins.
What is the glycine binding site of the NMDA receptor?
It is a conserved pocket in GluN1 and GluN3 subunits where glycine binds as an obligatory co-agonist for receptor activation.
How does ketamine affect glycine binding?
Ketamine binds within the NMDA receptor channel and modulates glycine-dependent gating, which is linked to its antidepressant and anesthetic effects.
Conclusion
Glycine binding (GO:0016594) is a fundamental molecular function that underlies fast inhibitory neurotransmission, NMDA receptor co-agonist gating, and RNA regulation by glycine-rich proteins. Its structural and pharmacological characterization has made the glycine binding site a prime target for drug discovery, with ketamine and betaine as notable examples. CRISPR-based models now allow researchers to test the causal roles of glycine-binding proteins in health and disease, accelerating functional validation and therapeutic development.
References
- 1. Yu A et al.. 2018. Glutamate and Glycine Binding to the NMDA Receptor.. Structure 26(7):1035-1043.e2 PMID: 29887499
- 2. Zhang Y et al.. 2021. Structural basis of ketamine action on human NMDA receptors.. Nature 596(7871):301-305 PMID: 34321660
- 3. Chang WT et al.. 2025. A new perspective on betaine: Targeting the glycine binding site of the NMDA receptor.. Biochem Pharmacol 242(Pt 3):117213 PMID: 40812583
- 4. Lühmann KL et al.. 2024. The glycine-rich domain of GRP7 plays a crucial role in binding long RNAs and facilitating phase separation.. Sci Rep 14(1):16018 PMID: 38992080
- 5. Xue G et al.. 2025. Dynamics and Interplay of the Binding Pockets in the Glycine Receptor.. J Chem Inf Model 65(15):8194-8206 PMID: 40742201
- 6. Sherman EM et al.. 2012. An energetically beneficial leader-linker interaction abolishes ligand-binding cooperativity in glycine riboswitches.. RNA 18(3):496-507 PMID: 22279151
- 7. Nilsson A et al.. 2007. Characterisation of the human NMDA receptor subunit NR3A glycine binding site.. Neuropharmacology 52(4):1151-9 PMID: 17320117
- 8. Ruff KM et al.. 2014. Ligand binding by the tandem glycine riboswitch depends on aptamer dimerization but not double ligand occupancy.. RNA 20(11):1775-88 PMID: 25246650
